CN109364286A - 一种氧化石墨烯复合纳米纤维结构敷料及制备方法 - Google Patents
一种氧化石墨烯复合纳米纤维结构敷料及制备方法 Download PDFInfo
- Publication number
- CN109364286A CN109364286A CN201811220706.3A CN201811220706A CN109364286A CN 109364286 A CN109364286 A CN 109364286A CN 201811220706 A CN201811220706 A CN 201811220706A CN 109364286 A CN109364286 A CN 109364286A
- Authority
- CN
- China
- Prior art keywords
- graphene oxide
- layer
- preparation
- fiber structure
- oxide composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229910021389 graphene Inorganic materials 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000002121 nanofiber Substances 0.000 title claims abstract description 32
- 239000002131 composite material Substances 0.000 title claims abstract description 23
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000000661 sodium alginate Substances 0.000 claims abstract description 31
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 31
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 31
- 239000002002 slurry Substances 0.000 claims abstract description 28
- 229910021536 Zeolite Inorganic materials 0.000 claims abstract description 18
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000010457 zeolite Substances 0.000 claims abstract description 18
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical compound [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 12
- VJVOFLWZDWLHNR-MRCUWXFGSA-N icosan-9-yl (z)-docos-13-enoate Chemical compound CCCCCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCC\C=C/CCCCCCCC VJVOFLWZDWLHNR-MRCUWXFGSA-N 0.000 claims abstract description 12
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 12
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 12
- 239000007921 spray Substances 0.000 claims abstract description 11
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 10
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 10
- 229960002477 riboflavin Drugs 0.000 claims abstract description 10
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 10
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000011701 zinc Substances 0.000 claims abstract description 8
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 8
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract 2
- 125000000914 phenoxymethylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 claims abstract 2
- 239000010410 layer Substances 0.000 claims description 70
- 239000000843 powder Substances 0.000 claims description 14
- 239000004744 fabric Substances 0.000 claims description 13
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims description 4
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- 239000011229 interlayer Substances 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims 1
- 239000011746 zinc citrate Substances 0.000 claims 1
- 235000006076 zinc citrate Nutrition 0.000 claims 1
- 229940068475 zinc citrate Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 abstract description 7
- 238000007711 solidification Methods 0.000 abstract description 6
- 230000008023 solidification Effects 0.000 abstract description 6
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 6
- 230000004888 barrier function Effects 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 4
- 206010042566 Superinfection Diseases 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 210000000416 exudates and transudate Anatomy 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- -1 it is dry Substances 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 3
- 230000001954 sterilising effect Effects 0.000 abstract description 3
- 206010013786 Dry skin Diseases 0.000 abstract description 2
- 230000007246 mechanism Effects 0.000 abstract description 2
- 238000005507 spraying Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 206010052428 Wound Diseases 0.000 description 17
- 208000027418 Wounds and injury Diseases 0.000 description 17
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000008113 selfheal Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01021—Non-adhesive bandages or dressings characterised by the structure of the dressing
- A61F13/01029—Non-adhesive bandages or dressings characterised by the structure of the dressing made of multiple layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Manufacturing & Machinery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明提供一种氧化石墨烯复合纳米纤维结构敷料及制备方法，先将纳米二氧化钛，沸石与PVA溶液混合搅拌均匀形成浆料，涂敷于承托层表面，干燥前喷涂一层0.2～2％的海藻酸钠溶液，40～75℃干燥，形成薄层，然后在薄层表面覆盖一层纳米纤维，接着涂覆由氧化石墨烯，海藻酸钠，透明质酸锌，维生素B2，维生素B12组成的浆料，干燥，喷洒少量锌盐溶液固化。本发明基于石墨烯的物理杀菌机理，结合纳米纤维膜的透气阻隔作用，负载有效成份制成结构敷料，通过各层对组织渗出液的吸收和消毒，保持伤口无菌状态，并提供必要营养物质，以避免伤口的二次感染，促进愈合，制备方法简单。
Description
技术领域
本发明涉及医用材料技术领域，具体涉及一种氧化石墨烯复合纳米纤维敷料及制备方法。
背景技术
皮肤受到创伤后使组织出现离断形成伤口，伤口局部有不同程度的组织坏死和血管断裂出血，数小时内便出现炎症反应，表现为充血、浆液渗出及白细胞游出，故局部红肿，并可能引起感染等并发症。伤口的修复是组织连续性和功能恢复的过程。伤口敷料是一种在伤口表面覆盖一层可以辅助身体促进伤口愈合的功能性医用辅料。它可以临时隔离伤口与外界环境，避免受到外部环境的感染。同时敷料中负载特定物质可以促进伤口愈合。
在伤口愈合过程中，病菌是导致伤口感染恶化的主要原因。研究表明，石墨烯具有抗菌和抑菌性能，其层状结构表面丰富的官能团还可以通过负载有效组分进一步对付病菌或病毒。
专利申请号为201810369012的发明专利涉及一种具有抑菌抗瘢痕双重作用的氧化石墨烯伤口敷料的制备方法，以氧化石墨烯作为原料，经过超声振荡分散、固液分离、药物负载三个基本程序而得到产品。该发明制备的氧化石墨烯敷料厚度可控，比表面积大，吸附性优良，强度和柔韧性好，无毒无菌，抑菌、抗瘢痕形成，对人体无刺激，与皮肤伤口无粘结性，环保；制备方法简单，操作方便，生产成本较低。该发明制备的伤口敷料可广泛用于常规及微创整形手术的伤口愈合及抗瘢痕形成，皮肤烧伤、挫伤等创面的愈合及抗瘢痕形成。该专利敷料无法给予伤口保湿性及营养供给以促进组织愈合，只起到在结构上隔离伤口，在抗菌方面防止感染的作用，并靠患者自身免疫能力自行愈合。
发明内容
为解决上述技术问题，本发明提供一种氧化石墨烯复合纳米纤维结构敷料，本发明基于石墨烯的物理杀菌机理，结合纳米纤维膜的透气阻隔作用，负载有效成份制成结构敷料，通过各层对组织渗出液的吸收和消毒，保持伤口无菌状态，并提供必要营养物质，以避免伤口的二次感染，促进愈合，制备方法简单。
本发明提供一种氧化石墨烯复合纳米纤维结构敷料，由三层结构组成，三层结构为承托层、中间层、内层，承托层、中间层、内层由上到下逐层设置。承托层厚度基本为布料本身厚度，中间层厚度为0.10～10微米、内层厚度为0.1～2微米，承托层、中间层、内层面积相同。
优选的是，所述承托层与空气接触，承托层采用普通医用网格物或织物中的至少一种制作而成。
上述任一方案优选的是，所述织物为无纺布。
上述任一方案优选的是，所述承托层上部涂覆有纳米二氧化钛、PVA、沸石粉制成的浆料。浆料的制备方法为：将聚乙烯醇粉末(PVA)用90～100℃的去离子水配成溶解质量浓度为0.1～6％溶液，然后加入纳米二氧化钛、沸石粉形成悬浊液，混合搅拌，迅速涂敷。为了防止悬浊液分层，涂敷时悬浊液不停地搅拌。二氧化钛、沸石粉与PVA的用量比为1：0.2～3：0.01～0.1。所述用量指质量。
上述任一方案优选的是，所述纳米二氧化钛、沸石粉与PVA的用量比为1：0.2～3：0.01～0.1。
上述任一方案优选的是，所述纳米二氧化钛、沸石粉与PVA的用量比为1：0.2：0.01。
上述任一方案优选的是，所述纳米二氧化钛、沸石粉与PVA的用量比为1：1：0.05。
上述任一方案优选的是，所述纳米二氧化钛、沸石粉与PVA的用量比为1：2：0.05。
上述任一方案优选的是，所述纳米二氧化钛、沸石粉与PVA的用量比为1：3：0.1。
上述任一方案优选的是，所述中间层采用纳米纤维制作而成，纳米纤维为PVA、PEO、PCL中的至少一种。
上述任一方案优选的是，所述内层与伤口接触，内层由氧化石墨烯、海藻酸钠、透明质酸锌、维生素B2、维生素B12制成的浆料涂覆而成。浆料的质量组成如下：水100份，氧化石墨烯0.2～8份，海藻酸钠0.1～3份，透明质酸锌0.05～4份，维生素B2为0.01～0.2份，维生素B12为0.01～0.1份；将上述组分混合搅拌均匀，形成氧化石墨烯和其他组分溶液组成的浆料。
本发明还提供一种氧化石墨烯复合纳米纤维结构敷料的制备方法，包括以下步骤：
(1)承托层的制备：将纳米二氧化钛、沸石与PVA溶液混合均匀形成浆料，涂敷于无纺布、织物或网格物表面，干燥前喷涂海藻酸钠溶液，干燥；
(2)中间层的制备：将纳米纤维覆盖在步骤(1)制备好的承托层表面；
(3)内层的制备：将氧化石墨烯、海藻酸钠、透明质酸锌、维生素B2、维生素B12、组成的浆料涂覆在中间层表面，干燥，再喷洒少量锌盐溶液，固化。
上述任一方案优选的是，所述步骤(1)中纳米二氧化钛、沸石粉与PVA的用量比为1：0.2～3：0.01～0.1。
上述任一方案优选的是，所述步骤(1)中承托层与空气接触，承托层采用网格物或织物中的至少一种制作而成。
上述任一方案优选的是，所述织物为无纺布。
上述任一方案优选的是，所述步骤(1)中喷涂的海藻酸钠溶液质量浓度为0.2～2％，喷涂量为20-100ml/m2。海藻酸钠为白色或淡黄色粉末，几乎无臭无味。海藻酸钠溶于水，不溶于乙醇、乙醚、氯仿等有机溶剂。溶于水后成粘稠状液体，1％水溶液pH值为6-8。当pH＝6-9时粘性稳定，加热至80℃以上时则粘性降低。海藻酸钠无毒，LD50>5000mg/kg。海藻酸钠微溶于水，不溶于大部分有机溶剂。它溶于碱性溶液，使溶液具有粘性。海藻酸钠粉末遇水变湿，微粒的水合作用使其表面具有粘性。然后微粒迅速粘合在一起形成团块，团块很缓慢的完全水化并溶解。如果水中含有其它与海藻酸盐竞争水合的化合物，则海藻酸钠更难溶解于水中。水中的糖、淀粉或蛋白质会降低海藻酸钠的水合速率，混合时间有必要延长。单价阳离子的盐(如NaCl)在浓度高于0.5％时也会有类似的作用。海藻酸钠在1％的蒸馏水溶液中的pH值约为7.2。海藻酸钠具有吸湿性，平衡时所含水分的多少取决于相对湿度。干燥的海藻酸钠在密封良好的容器内于25℃及以下温度储存相当稳定。海藻酸钠溶液在pH5～9时稳定。
上述任一方案优选的是，所述步骤(1)中在40～75℃干燥25～60min。
上述任一方案优选的是，所述步骤(2)中纳米纤维为PVA、PEO、PCL中的至少一种。
上述任一方案优选的是，所述步骤(3)中干燥温度为35～65℃，干燥时间为30～50min。
上述任一方案优选的是，所述步骤(3)中锌盐溶液为氯化锌、醋酸锌、硝酸锌、柠檬酸锌溶液中的至少一种，质量浓度1％～2％，喷洒量为10～60ml/m2。
上述任一方案优选的是，所述步骤(3)中固化温度为35～75℃，固化时间为20～75min。
本发明的上述技术方案的有益效果如下：本发明提供一种氧化石墨烯复合纳米纤维结构敷料的制备方法，首先将纳米二氧化钛，沸石与PVA溶液混合搅拌均匀形成浆料，涂敷于承托层表面，干燥前喷涂一层0.2～2％的海藻酸钠溶液，40～75℃干燥，形成薄层，然后在薄层表面覆盖一层纳米纤维，接着涂覆由氧化石墨烯，海藻酸钠，透明质酸锌，维生素B2，维生素B12组成的浆料，干燥，喷洒少量锌盐溶液固化。本发明基于石墨烯的物理杀菌机理，结合纳米纤维膜的透气阻隔作用，负载有效成份制成结构敷料，通过各层对组织渗出液的吸收和消毒，保持伤口无菌状态，并提供必要营养物质，以避免伤口的二次感染，促进愈合，制备方法简单。
附图说明
图1为本发明的氧化石墨烯复合纳米纤维结构敷料的结构示意图。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚，下面将结合附图及具体实施例进行详细描述。
实施例1
氧化石墨烯复合纳米纤维结构敷料的制备方法如下，如图1所示：
(1)承托层100的制备：将纳米二氧化钛、沸石与PVA(用量比为1：0.2：0.03)溶液混合搅拌均匀形成浆料，涂敷于无纺布、织物或网格物表面，干燥前喷涂一层1％的海藻酸钠溶液50ml/m2，50℃干燥30min，形成薄层。
(2)中间层200的制备：在步骤(1)制备的薄层表面覆盖纳米纤维膜PVA200。纤维膜的克重为2g/m2。
(3)内层300的制备：在中间层上部涂覆由氧化石墨烯，海藻酸钠，透明质酸锌，维生素B2，维生素B12和水，组成的浆料。浆料的质量组成如下：水100份，氧化石墨烯0.5份，海藻酸钠0.25份，透明质酸锌0.06份，维生素B2为0.015份，维生素B12为0.01份。将这些组分混合搅拌均匀，形成氧化石墨烯和其他组分溶液组成的浆料。40℃干燥25min，再喷洒少量氯化锌溶液(15ml/m2)，在40℃固化35min。
实施例2
氧化石墨烯复合纳米纤维结构敷料的制备方法如下：
(1)承托层100的制备：将纳米二氧化钛、沸石与PVA(1：1：0.02)溶液混合搅拌均匀形成浆料，涂敷于无纺布，织物或网格物表面，干燥前喷涂一层0.2％的海藻酸钠溶液(25ml/m2)，45℃干燥25min，形成薄层。
(2)中间层200的制备：在薄层表面覆盖纳米纤维膜PVA。纤维膜的克重为2g/m2。
(3)内层300的制备：在中间层上部涂覆由氧化石墨烯，海藻酸钠，透明质酸锌，维生素B2，维生素B12组成的浆料，浆料的组成如下：水100份，氧化石墨烯3份，海藻酸钠1.6份，透明质酸锌2.6份，维生素B2为0.10份，维生素B12为0.08份。将这些组分混合搅拌均匀形成氧化石墨烯和其他组分溶液组成的浆料。40℃干燥25min，再喷洒少量氯化锌溶液(15ml/m2)，在40℃固化35min。
实施例3
氧化石墨烯复合纳米纤维结构敷料的制备方法如下：
(1)承托层100的制备：将纳米二氧化钛、沸石与PVA(1：2.8：0.08)溶液混合搅拌均匀形成浆料，涂敷于无纺布，织物或网格物表面，干燥前喷涂一层0.5％的海藻酸钠溶液(80ml/m2)，70℃干燥45min，形成薄层。
(2)中间层200的制备：在薄层表面覆盖纳米纤维膜PVA。纤维膜的克重为3.5g/m2。
(3)内层300的制备：在中间层上部涂覆由氧化石墨烯，海藻酸钠，透明质酸锌，维生素B2，维生素B12等组成的浆料，浆料的组成如下：水100份，氧化石墨烯7.3份，海藻酸钠2.4份，透明质酸锌3.7份，维生素B2为0.17份，维生素B12为0.08份。将这些组分混合搅拌均匀形成氧化石墨烯和其他组分溶液组成的浆料。50℃干燥35min，再喷洒少量氯化锌溶液(55ml/m2)，在60℃固化55min。
上述实施例所得的结构性敷料按照AATCC-100-2012试验法进行抗菌率测试抗菌性能如表1所示：
表1本发明制备的结构性敷料抗菌性能测试结果
本发明实施例结构敷料根据GB/T12704-1991织物透湿量测定方法透湿杯法，测定本发明制得复合面料的性能，透湿性能如表2所示：
表2本发明实施例结构敷料的透湿性能测试结果
*其中，人体无汗日透湿量约2500g/m2·24h。
从上述结果可以看出，石墨烯的含量显著影响透湿率，含量越高，透湿率明显下降。从透湿量看，所得敷料透湿性能良好，明显高于人体无汗时水分蒸发量2500ml/m2·24h。更结合纳米纤维膜的透气阻隔作用，使敷料具备较好透气性。同时抗菌数据显示敷料对于金黄色葡萄球菌的抗菌性能随着石墨烯的含量增加而呈现一定增强的趋势，其均表现出很好的抗菌性能。
以上详细描述了本发明的较佳具体实施例。应当理解，本领域的普通技术人员无需创造性劳动就可以根据本发明的构思作出诸多修改和变化。因此，凡本技术领域中技术人员依本发明的构思在现有技术的基础上通过逻辑分析、推理或者有限的实验可以得到的技术方案，皆应在由权利要求书所确定的保护范围内。
Claims (10)
1.一种氧化石墨烯复合纳米纤维结构敷料，其特征在于，包括三层结构，三层结构为承托层、中间层、内层，承托层、中间层、内层由上到下逐层设置。
2.如权利要求1所述的一种氧化石墨烯复合纳米纤维结构敷料，其特征在于，所述承托层与空气接触，承托层采用普通医用网格物或织物中的至少一种制作而成。
3.如权利要求1所述的一种氧化石墨烯复合纳米纤维结构敷料，其特征在于，所述承托层上部涂覆有纳米二氧化钛、PVA、沸石粉制成的浆料。
4.如权利要求1所述的一种氧化石墨烯复合纳米纤维结构敷料，其特征在于，所述中间层采用纳米纤维制作而成，纳米纤维为PVA、PEO、PCL中的至少一种。
5.如权利要求1所述的一种氧化石墨烯复合纳米纤维结构敷料，其特征在于，所述内层与伤口接触，内层由氧化石墨烯、海藻酸钠、透明质酸锌、维生素B2、维生素B12制成的浆料涂覆而成。
6.一种氧化石墨烯复合纳米纤维结构敷料的制备方法，其特征在于，包括以下步骤：
(1)承托层的制备：将纳米二氧化钛、沸石与PVA溶液混合均匀形成浆料，涂敷于无纺布、织物或网格物表面，干燥前喷涂海藻酸钠溶液，干燥；
(2)中间层的制备：将纳米纤维覆盖在步骤(1)制备好的承托层表面；
(3)内层的制备：将氧化石墨烯、海藻酸钠、透明质酸锌、维生素B2、维生素B12、组成的浆料涂覆在中间层表面，干燥，再喷洒少量锌盐溶液，固化。
7.如权利要求6所述的一种氧化石墨烯复合纳米纤维结构敷料的制备方法，其特征在于，所述步骤(1)中纳米二氧化钛、沸石粉与PVA的用量比为1：0.2～3：0.01～0.1。
8.如权利要求6所述的一种氧化石墨烯复合纳米纤维结构敷料的制备方法，其特征在于，所述步骤(1)中喷涂的海藻酸钠溶液为0.2～2％，喷涂量为20～100ml/m2。
9.如权利要求6所述的一种氧化石墨烯复合纳米纤维结构敷料的制备方法，其特征在于，所述步骤(2)中纳米纤维为PVA、PEO、PCL中的至少一种。
10.如权利要求6所述的一种氧化石墨烯复合纳米纤维结构敷料的制备方法，其特征在于，所述步骤(3)中锌盐溶液为氯化锌、醋酸锌、硝酸锌、柠檬酸锌溶液中的至少一种，喷洒量为10～60ml/m2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811220706.3A CN109364286B (zh) | 2018-10-19 | 2018-10-19 | 一种氧化石墨烯复合纳米纤维结构敷料及制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811220706.3A CN109364286B (zh) | 2018-10-19 | 2018-10-19 | 一种氧化石墨烯复合纳米纤维结构敷料及制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109364286A true CN109364286A (zh) | 2019-02-22 |
| CN109364286B CN109364286B (zh) | 2021-08-06 |
Family
ID=65400383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811220706.3A Active CN109364286B (zh) | 2018-10-19 | 2018-10-19 | 一种氧化石墨烯复合纳米纤维结构敷料及制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109364286B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111744050A (zh) * | 2020-07-15 | 2020-10-09 | 中国人民解放军西部战区总医院 | 氧化石墨烯-达托霉素∕表皮生长因子复合敷料制备及创面愈合方法 |
| CN115282325A (zh) * | 2022-07-08 | 2022-11-04 | 海雅美生物技术(珠海)有限公司 | 一种用于创面修复的凝胶敷料及其制备工艺 |
| CN115957367A (zh) * | 2022-12-02 | 2023-04-14 | 浙江兄弟控优生物科技有限公司 | 一种高生物相容性涂覆液及疏水抗菌纱布敷料 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133421A (zh) * | 2011-03-17 | 2011-07-27 | 山东赛克赛斯药业科技有限公司 | 一种快速止血创伤敷料及其制备方法与应用 |
| CN103920179A (zh) * | 2014-04-22 | 2014-07-16 | 楚立云 | 一种石墨烯伤口敷料 |
| KR20150098010A (ko) * | 2014-02-19 | 2015-08-27 | 금오공과대학교 산학협력단 | 항균 폴리우레탄 폼 드레싱재 및 그 제조방법 |
| CN105617441A (zh) * | 2016-03-16 | 2016-06-01 | 腾科宝迪（厦门）生物科技有限公司 | 一种石墨烯抗菌敷料 |
| CN107753182A (zh) * | 2017-11-26 | 2018-03-06 | 山东朱氏药业集团有限公司 | 一种络合碘石墨烯无纺布敷料 |
| CN108187120A (zh) * | 2018-02-06 | 2018-06-22 | 重庆医科大学附属永川医院 | 一种麻醉科医用止痛止血敷料及其制备方法 |
-
2018
- 2018-10-19 CN CN201811220706.3A patent/CN109364286B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102133421A (zh) * | 2011-03-17 | 2011-07-27 | 山东赛克赛斯药业科技有限公司 | 一种快速止血创伤敷料及其制备方法与应用 |
| KR20150098010A (ko) * | 2014-02-19 | 2015-08-27 | 금오공과대학교 산학협력단 | 항균 폴리우레탄 폼 드레싱재 및 그 제조방법 |
| CN103920179A (zh) * | 2014-04-22 | 2014-07-16 | 楚立云 | 一种石墨烯伤口敷料 |
| CN105617441A (zh) * | 2016-03-16 | 2016-06-01 | 腾科宝迪（厦门）生物科技有限公司 | 一种石墨烯抗菌敷料 |
| CN107753182A (zh) * | 2017-11-26 | 2018-03-06 | 山东朱氏药业集团有限公司 | 一种络合碘石墨烯无纺布敷料 |
| CN108187120A (zh) * | 2018-02-06 | 2018-06-22 | 重庆医科大学附属永川医院 | 一种麻醉科医用止痛止血敷料及其制备方法 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111744050A (zh) * | 2020-07-15 | 2020-10-09 | 中国人民解放军西部战区总医院 | 氧化石墨烯-达托霉素∕表皮生长因子复合敷料制备及创面愈合方法 |
| CN115282325A (zh) * | 2022-07-08 | 2022-11-04 | 海雅美生物技术(珠海)有限公司 | 一种用于创面修复的凝胶敷料及其制备工艺 |
| CN115957367A (zh) * | 2022-12-02 | 2023-04-14 | 浙江兄弟控优生物科技有限公司 | 一种高生物相容性涂覆液及疏水抗菌纱布敷料 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109364286B (zh) | 2021-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100411690C (zh) | 一种抑菌聚电解质多孔材料的制备方法 | |
| CN109364286A (zh) | 一种氧化石墨烯复合纳米纤维结构敷料及制备方法 | |
| CN106267300B (zh) | 一种兼具杀菌止血性和生化战剂防护性的多功能材料及其制备方法 | |
| CN102061625B (zh) | 一种艾叶油微胶囊抗菌防皱织物及其制备方法 | |
| Wang et al. | Facile fabrication of carboxymethyl chitosan/paraffin coated carboxymethylated cotton fabric with asymmetric wettability for hemostatic wound dressing | |
| CN105709262A (zh) | 一种载银抗菌敷料及其制备方法 | |
| CN107261196A (zh) | 一种抗菌丝素蛋白材料及其制备方法 | |
| CN104623722A (zh) | 一种海藻酸抗菌止血海绵材料及制备方法 | |
| CN105664225A (zh) | 一种纳米银、壳聚糖和蚕丝蛋白复合生物敷料及其制备方法 | |
| CN102908653A (zh) | 一种用于深度感染性伤口的抗菌敷料制备方法 | |
| CN209301808U (zh) | 一种沸石壳聚糖复合止血纱布 | |
| CN109252246A (zh) | 一种水溶性海藻酸盐抗菌纤维及其制备方法 | |
| CN101721734A (zh) | 医用海藻酸钙抗菌敷料及其制备方法 | |
| CN109731121A (zh) | 一种含有介孔二氧化硅的纤维素和壳聚糖复合敷料的制备方法 | |
| CN108126231A (zh) | 一种高强度抑菌医用纱布的制备方法 | |
| CN107296975A (zh) | 一种抗菌止血复合医用敷料及其制备方法 | |
| CN104491918A (zh) | 一种新型抗菌水胶体敷料及其制备方法 | |
| CN104231299A (zh) | 一种载银介孔硅/胶原/缩醛化聚乙烯醇抗菌敷料的制备方法 | |
| CN103074777A (zh) | 一种载银海藻酸纤维及其制备方法 | |
| Li et al. | Construction of porous structure-based carboxymethyl chitosan/sodium alginate/tea polyphenols for wound dressing | |
| Wang et al. | Multifunctional Asymmetric Bacterial Cellulose Membrane with Enhanced Anti‐Bacterial and Anti‐Inflammatory Activities for Promoting Infected Wound Healing | |
| CN109276743A (zh) | 一种促进伤口愈合的速效止血纱及其制备方法和应用 | |
| Shi et al. | Studies of the properties of CHG-Loaded alginate fibers for medical application | |
| CN104606710B (zh) | 一种高抗菌性藻酸盐敷料的制备方法 | |
| CN107469141A (zh) | 一种微海绵医用敷料及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 230088 507-1, R & D building, Hefei Institute of technology innovation, Chinese Academy of Sciences, northwest corner of intersection of Xiyou road and Shilian South Road, high tech Zone, Hefei City, Anhui Province Applicant after: Hefei Zhongke Weiyun Technology Co.,Ltd. Address before: 230088 507-1, R & D building, Hefei Institute of technology innovation, Chinese Academy of Sciences, northwest corner of intersection of Xiyou road and Shilian South Road, high tech Zone, Hefei City, Anhui Province Applicant before: HEFEI ZHONGKE WEIYUN HEALTH TECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |